摘要
目的探讨参麦注射液配合常规疗法治疗支气管哮喘急性发作的临床疗效及其对T淋巴细胞免疫功能的影响。方法将118例支气管哮喘急性发作期患者随机分为研究组和对照组,每组59例。对照组给予常规西医治疗,研究组在此基础上加用参麦注射液60mL,1次/天,连用14d,观察两组临床疗效及治疗前、后外周血中T淋巴细胞(CD4+、CD8+、CD4+/CD8+、CD69CD3+T淋巴细胞、CD69CD4+T淋巴细胞)水平的变化。结果研究组有效率为91.53%,对照组有效率为71.19%,差异有统计学意义(P<O.01)。研究组治疗后CD4+、CD4+/CD8+、CD69CD3+T淋巴细胞和CD69CD4+T淋巴细胞明显降低([35.00±2.55)%比(50.64±3.52)%,(1.18±0.61)比(2.30±0.31),(5.88±0.59)%比(9.23±0.90)%,(3.73±0.56)%比(6.52±0.67)%],CD8+明显增高([34.98±2.56)%比(25.93±2.57)%](P<0.01或P<0.05),对照组治疗前、后无明显变化。结论在常规疗法基础上加用参麦注射液治疗支气管哮喘急性发作能明显提高临床疗效,这与参麦注射液能改善T淋巴细胞的免疫功能有关。
Objective To observe effects of Shenmai injection combined with routine methods in acute bronchial asthma and immune function of T lymphocyte. Methods 118 patients with acute exacerbation of bronchial asthma were randomly divided into the research group and the control group, each group had 59 cases. The patients in control group were treated with routine western medicine, while the patients in research group, based on the same therapy as control group, were treated with Shenmai injection 60ml a day infused intravenously for 14 days. The effects of treatment and the change of T cell leves （CD4＋, CD8＋, CD4＋/CD8＋, CD69CD3＋, CD69CD4＋） in peripheral blood were observed. Results The research group effective rate was 91.53%, control group was 71.19%. Diference was apparent （P〈0.01）. The levels of CD4＋, CD4＋/CD8＋, CD69CD3＋, CD69CD4＋ significantly decreased and CD8＋ increased in research group[（35.00＋2.55）% vs （50.64±3.52）%, （1.18±0.61） vs （2.30±0.31）, （5.88±0.59）% vs （9.23±0.90）%, （3.73±0.56）% vs （6.52±0.67）%, （34.98±2.56）% vs （25.93±2.57）%]（P〈0.01 or P〈0.05）. There were no marked change in control group. Conclusion Shenmai injection combined with routine treatment can increase the therapeutic effect on acute exacerbation of bronchial asthma, the mechanism may be that Shenmai injection may improve the immune function of T lymphocyte.
出处
《当代医学》
2012年第29期84-86,共3页
Contemporary Medicine
